The Binding of Silibinin, the Main Constituent of Silymarin, to Site I on Human Serum Albumin-Reference-Cited by-同舟云学术

The Binding of Silibinin, the Main Constituent of Silymarin, to Site I on Human Serum Albumin

Published:2017 Issue:3 Volume:40 Page:310-317
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Yamasaki Keishi¹²,Sato Hiroki³,Minagoshi Saori¹,Kyubun Karin¹,Anraku Makoto¹²,Miyamura Shigeyuki³,Watanabe Hiroshi³,Taguchi Kazuaki¹,Seo Hakaru¹²,Maruyama Toru³,Otagiri Masaki¹²

Affiliation:

1. Faculty of Pharmaceutical Sciences, Sojo University

2. DDS Research Institute, Sojo University

3. Graduate School of Pharmaceutical Sciences, Kumamoto University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/40/3/40_b16-00790/_pdf

Reference50 articles.

1. 1) Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs, 15, 465–489 (2001).

2. 2) Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr. Cancer Ther., 6, 110–119 (2007).

3. 3) Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother. Res., 24, 1423–1432 (2010).

4. 4) Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol., 17, 2288–2301 (2011).

5. 5) Kren V, Walterova D. Silybin and silymarin—new effects and applications. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 149, 29–41 (2005).

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioactive compounds: Application of albumin nanocarriers as delivery systems;Critical Reviews in Food Science and Nutrition;2022-03-03

2. Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling;Journal of Pharmacokinetics and Pharmacodynamics;2022-01-21

3. Interactions of bioflavonoids and other polyphenolic-type nutraceuticals with drugs;Functional Foods and Nutraceuticals in Metabolic and Non-Communicable Diseases;2022

4. Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes;Biomedicine & Pharmacotherapy;2021-06

5. Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin;Medicinal Research Reviews;2021-02-15